Tofacitinib PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering Tofacitinib — currently 2 formulations in tablet form — to distributors and franchise partners across India. The products are manufactured at approved facilities and offered with district-level monopoly rights, so a partner building rheumatology coverage keeps the territory to themselves.

What is Tofacitinib?

Tofacitinib is an oral Janus kinase (JAK) inhibitor — a targeted synthetic disease-modifying antirheumatic drug. It blocks JAK1 and JAK3 signalling inside immune cells, interrupting the cytokine pathways that drive chronic inflammation and joint destruction in autoimmune disease. Unlike biologic DMARDs, which must be injected, Tofacitinib achieves comparable pathway blockade with a tablet. It is an immunosuppressant, is prescription-only, and is initiated by a specialist after screening for latent tuberculosis and other infections. Compound and pharmacology data are available on PubChem.

Tofacitinib Formulations Available with Cafoli Lifecare

The Tofacitinib portfolio comprises 2 formulations, supplied as tablets. Strength, packing and net rate details are shared with registered franchise enquiries.

Therapeutic Applications of Tofacitinib

• Moderate to severe rheumatoid arthritis, in patients with an inadequate response to conventional DMARDs
• Psoriatic arthritis
• Moderately to severely active ulcerative colitis
• Ankylosing spondylitis, at the specialist's discretion

Prescribers are rheumatologists, gastroenterologists and dermatologists working in autoimmune disease. Ongoing monitoring for infection, blood counts and lipid profile is part of standard therapy, and treatment is always specialist-supervised.

Why Tofacitinib is a High-Potential Molecule for Distributors

The economics of autoimmune care in India are being rewritten by oral JAK inhibitors. A patient who would once have needed injectable biologics — expensive, cold-chain dependent, and out of reach for most families — can now be treated with a daily tablet at a fraction of the cost. That has pulled a large number of rheumatoid arthritis and ulcerative colitis patients into active treatment who previously stayed on symptomatic therapy. For a distributor, the profile is unusually favourable: therapy is chronic and continuous, so each patient represents years of monthly refills; the prescriber base is tiny and geographically concentrated, so a single rheumatologist relationship can carry meaningful volume; and value per pack is high, so revenue does not depend on shifting large quantities. The counterweight is that this is a serious immunosuppressant — the copy, the detailing and the positioning must stay strictly clinical and prescription-led.

Why Choose Cafoli Lifecare for Your Tofacitinib Franchise

• Monopoly rights — one partner per district, territory protected
• WHO-GMP certified manufacturing and DCGI-approved formulations
• Promotional inputs — visual aids, doctor literature, reminder gifts and MR bags
• 1000+ franchise partners across India
• On-time despatch, transparent net rates and dedicated order support

References

1. PubChem — Tofacitinib compound record, National Library of Medicine
2. PubMed — clinical literature on tofacitinib in rheumatoid arthritis
3. WHO Model List of Essential Medicines